<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-1249</journal-id>
<journal-title><![CDATA[Archivos de Pediatría del Uruguay]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Pediatr. Urug.]]></abbrev-journal-title>
<issn>1688-1249</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Uruguaya de Pediatría]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-12492018000400034</article-id>
<article-id pub-id-type="doi">10.31134/ap.89.s1.4</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Nivel de calprotectina fecal en niños sanos menores de 4 años]]></article-title>
<article-title xml:lang="en"><![CDATA[Fecal calprotectin levels in healthy children younger than 4 years old]]></article-title>
<article-title xml:lang="pt"><![CDATA[Nível de calprotectina fecal em crianças saudáveis com menos de 4 anos de idade]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Dewaele]]></surname>
<given-names><![CDATA[Rita]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Delgado]]></surname>
<given-names><![CDATA[Laura]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Florio]]></surname>
<given-names><![CDATA[Lucia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carabio]]></surname>
<given-names><![CDATA[Claudio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Iglesias]]></surname>
<given-names><![CDATA[Claudio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,CHPR Servicio Gastroenterología, Hepatología y Nutrición Pediátrica. Videoendoscopía Digestiva ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,CHPR Servicio Gastroenterología, Hepatología y Nutrición Pediátrica. Videoendoscopía Digestiva ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af3">
<institution><![CDATA[,UDELAR Facultad de Medicina Centro Cardiovascular Universitario]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,UDELAR Facultad de Ciencias ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,CHPR Servicio Gastroenterología, Hepatología y Nutrición Pediátrica. Videoendoscopía Digestiva ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2018</year>
</pub-date>
<volume>89</volume>
<fpage>34</fpage>
<lpage>40</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-12492018000400034&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-12492018000400034&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-12492018000400034&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción: la calprotectina es una proteína del citoplasma de neutrófilos, con propiedades bacteriostáticas. Aumenta en materia fecal en procesos inflamatorios de la mucosa intestinal, siendo un marcador de inflamación. Su cuantificación es un método no invasivo y estable en su procesamiento. Presenta una alta sensibilidad para diferenciar entre enfermedad orgánica y funcional y tiene alto valor predictivo positivo para hallazgo de lesiones a nivel endoscópico. Presenta baja especificidad para diferenciar la etiología de la inflamación. El nivel de calprotectina fecal (CF) es variable de acuerdo a la edad. En niños menores de 4 años se han encontrado concentraciones mayores que en otras edades. Esto se puede explicar por factores como: mayor migración de neutrófilos en la mucosa durante el desarrollo de tolerancia oral, regulación de la microbiota intestinal, inmadurez de la barrera epitelial y el ambiente que rodea al niño con permanente estímulo para su sistema inmunológico. Por lo que no se ha podido establecer el cut off en esta franja etaria.  Objetivo: conocer los valores de la CF en niños sanos menores de 4 años para determinar valor normal o cut off. Determinarlo según grupos etarios y por sexo.  Método: estudio descriptivo con componente analítico. Se obtiene la muestra de los niños que realizan el coproparasitario para el ingreso escolar. Catalogados como sanos: sin antecedentes personales de enfermedad crónica, sin síntomas por lo menos cuatro semanas anteriores a la toma de la muestra. Buen crecimiento según las curvas OMS. Distribuidos en diferentes regiones geográficas de la zona metropolitana de Montevideo. Se utilizó el kit RIDASCREEN®.  Resultados:  fueron analizadas 155 muestras; 73 de sexo femenino y 82 sexo masculino. Se distribuyeron en grupos etarios: menor de 1 año (n=11); 1 a 2 años (n=36); 2 a 3 años (n=45); 3 a 4 años (n=63). La mediana fue de 152,2 mg/kg (percentil 50). Rango de 4,1 a 1944 mg/kg. Nuestro cut off fue de 954 mg/kg (percentil 95). Se aplica Wilcoxon test p=0,68 y test Kruskal Wallis p=0,06, sin diferencias significativas entre sexo y grupos etarios respectivamente.  Conclusiones: es el primer estudio de CF en una población de niños sanos menores de 4 años en Latinoamérica. La mediana encontrada es mayor que la habitual en niños mayores de 4 años y adultos. Obtuvimos un límite normal de 954 mg/kg. No se encontró diferencia en la concentración según sexo o rango etario. Limitaciones de nuestro estudio: el tamaño y la obtención de la muestra corresponde solamente al departamento de Montevideo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary:  Introduction:  calprotectin is a protein with bacteriostatic properties, found in cytoplasmic neutrophils. Concentration in fecal matter increases in inflammatory processes of the intestinal mucous membrane, being it an inflammation marker. Quantification involves a non-invasive method, stable during processing. Fecal calprotectin concentration is highly sensitive to differentiate between organic and functional disease and has a high positive predictive value for the finding of endoscopic lesions. It evidences low specificity to distinguish the inflammation&#8217;s etiology. Fecal calprotectin concentration (FCC) varies according to age. Higher concentrations have been found in children younger than 4 years old, what may be explained by the following factors: greater migration of neutrophils in the mucous during the development of oral tolerance, regulation of gut microbiota, non-mature epithelial tissue and the context the child grows in as a permanent stimulation for his immune system. Thus, cut off has not been established yet for this age group.  Objective:  to learn about FCC in healthy children younger than 4 years old to determine normal values or cut off. To determine values according to age and sex.  Method:  descriptive study with an analytic component. A sample of the children who undergo a coproparsitary test upon entering school is taken. A healthy child is regarded to: have no personal history of chronic disease, no symptoms at least in the 4 weeks prior to the sample being taken. Good growth is defined as per the WHO curves. Samples included came from different regions in the Montevideo metropolitan area. The RIDASCREEN® kit was used.  Results:  155 samples were analysed, 73 of them corresponding to boys and 82 to girls. As to age: younger than 1 year old (n= 11), from 1 to 2 years old (n= 36), from 2 to 3 years old (n= 45), from 3 to 4 years old (n= 63). Median concentration was 152.2 mg/kg (Percentile 50). Range 4.1 to 1944 mg/kg. Our cut off was 954 mg/kg (percentile 95). Wolcoxon test was applied (p= 0.68) and Kruskal Wallis test (p=0.06), no significant differences were found between sex and age groups respectively. We obtained a normal limit of 954 mg/Kg. No difference was found in the concentration for different sex or age. Limitations of our study result from the size of the sample and the fact that all samples correspond to Montevideo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  a calprotectina é uma proteína neutrofílica citoplasmática com propriedades bacteriostáticas. Ela aumenta na matéria fecal durante os processos inflamatórios da mucosa intestinal, e é um marcador de inflamação. Pode ser quantificada utilizando um método não invasivo, estável em seu processamento. Apresenta alta sensibilidade para diferenciar entre doença orgânica e funcional e tem alto valor preditivo positivo para encontrar lesões no nível endoscópico. Apresenta baixa especificidade para diferenciar a etiologia da inflamação. O nível de calprotectina fecal (CF) varia de acordo com a idade, e para o caso de crianças com menos de 4 anos ela teve concentrações mais elevadas, o que pode ser explicado por fatores tais como o aumento da migração de neutrófilos na mucosa durante o desenvolvimento de tolerância oral, regulação da microbiota intestinal, imaturidade da barreira epitelial e ambiente que envolve a criança como estímulo permanente do sistema imunológico. Portanto, não foi possível estabelecer o corte nesta faixa etária.  Objetivo:  conhecer os valores da FC em crianças saudáveis menores de 4 anos para determinar o valor normal ou o de corte de acordo com as faixas etárias e sexo.  Método:  estudo descritivo com componente analítico. A amostra foi obtida das crianças que realizaram o estudo coproparasitológico para a admissão escolar. Crianças catalogadas como saudáveis: sem histórico de doença crônica, sem sintomas durante pelo menos 4 semanas antes de experimentar a amostra. Bom crescimento: de acordo com as curvas da OMS. Distribuído em diferentes regiões geográficas da área metropolitana de Montevidéu. Se utilizou o kit RIDASCREEN®.  Resultados:  foram analisadas 155 amostras: 73 de mulheres e 82 de homens distribuídos em grupos etários: com menos de 1 ano (n = 11), 1 a 2 anos (n = 36), 2 a 3 anos (n = 45), 3 a 4 anos (n = 63). A mediana foi de 152,2 mg / kg (percentil 50). Faixa de 4,1 a 1944 mg / kg. Nosso corte foi 954mg / Kg (percentil 95). Aplicou-se o teste de Wilcoxon p = 0,68 e o teste de Kruskal Wallis p = 0,06, e não observamos diferenças significativas entre os grupos por sexo ou faixa etária, respectivamente.  Conclusões:  este foi o primeiro estudo de FC numa população de crianças saudáveis com menos de 4 anos de idade na América Latina. A mediana encontrada é maior que a usual em crianças com mais de 4 anos e em adultos. Obtivemos um limite normal de 954mg / Kg. Nenhuma diferença foi encontrada na concentração dependendo do sexo ou faixa etária. As limitações do nosso estudo são o tamanho da amostra e o fato de que a amostra foi obtida apenas de Montevidéu.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Complejo de antígeno L1 de leucocito]]></kwd>
<kwd lng="en"><![CDATA[Leukocyte L1 antigen complex]]></kwd>
<kwd lng="pt"><![CDATA[Complexo antígeno L1 leucocitário]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steinbakk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Naess]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lingaas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Dale]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Brandtzaeg]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fagerhol]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1990</year>
<volume>336</volume>
<numero>8718</numero>
<issue>8718</issue>
<page-range>763-5</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johne]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Fagerhol]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Lyberg]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Prydz]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Brandtzaeg]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Naess]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Functional and clinical aspects of the myelomonocyte protein calprotectin]]></article-title>
<source><![CDATA[Mol Pathol]]></source>
<year>1997</year>
<volume>50</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>113-23</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Henderson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2014</year>
<volume>109</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>637-45</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Henderson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Casey]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lawrence]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kingstone]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2012</year>
<volume>107</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>941-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olafsdottir]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Aksnes]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fluge]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Berstad]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children]]></article-title>
<source><![CDATA[Acta Paediatr]]></source>
<year>2002</year>
<volume>91</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>45-50</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kostakis]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Cholidou]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Vaiopoulos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vlachos]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Perrea]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Vaos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fecal calprotectin in pediatric inflammatory bowel disease a systematic review]]></article-title>
<source><![CDATA[Dig Dis Sci]]></source>
<year>2013</year>
<volume>58</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>309-19</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carroccio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Iacono]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cottone]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Di Prima]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cartabellotta]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cavataio]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome a prospective study in adults and children]]></article-title>
<source><![CDATA[Clin Chem]]></source>
<year>2003</year>
<volume>49</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>861-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fagerberg]]></surname>
<given-names><![CDATA[UL]]></given-names>
</name>
<name>
<surname><![CDATA[Lööf]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Myrdal]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Finkel]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms]]></article-title>
<source><![CDATA[J Pediatr Gastroenterol Nutr]]></source>
<year>2005</year>
<volume>40</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>450-5</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bunn]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bisset]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Main]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Golden]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease]]></article-title>
<source><![CDATA[J Pediatr Gastroenterol Nutr]]></source>
<year>2001</year>
<volume>32</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>171-7</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Røseth]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fagerhol]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Aadland]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Schjønsby]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of the neutrophil dominating protein calprotectin in feces A methodologic study]]></article-title>
<source><![CDATA[Scand J Gastroenterol]]></source>
<year>1992</year>
<volume>27</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>793-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<collab>National Institute for Health and Care Excellence</collab>
<source><![CDATA[Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel. Diagnostics guidance DG11]]></source>
<year>2013</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[NICE]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rugtveit]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fagerhol]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Age-dependent variations in fecal calprotectin concentrations in children]]></article-title>
<source><![CDATA[J Pediatr Gastroenterol Nutr]]></source>
<year>2002</year>
<volume>34</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>323-4</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oord]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hornung]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fecal calprotectin in healthy children]]></article-title>
<source><![CDATA[Scand J Clin Lab Invest]]></source>
<year>2014</year>
<volume>74</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>254-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Geng]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fecal calprotectin concentrations in healthy children aged 1-18 months]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2015</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fagerberg]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Lööf]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Merzoug]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Finkel]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fecal calprotectin levels in healthy children studied with an improved assay]]></article-title>
<source><![CDATA[J Pediatr Gastroenterol Nutr]]></source>
<year>2003</year>
<volume>37</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>468-72</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hestvik]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Tumwine]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Tylleskar]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Grahnquist]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ndeezi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kaddu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Faecal calprotectin concentrations in apparently healthy children aged 0-12 years in urban Kampala, Uganda a community-based survey]]></article-title>
<source><![CDATA[BMC Pediatr]]></source>
<year>2011</year>
<volume>11</volume>
<page-range>9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roba]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Medición de la pobreza infantil en Uruguay]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[Centro Interdisciplinario de Infancia y Pobreza]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
